Patient: Faster results
Despite efforts to optimize disease management, only one-third of newly diagnosed CML patients are adequately monitored during the first year of treatment.7
Therefore, more accessible molecular testing is needed to enhance CML patient outcomes.Clinician: Same day information supports informed clinical decisions.
Timely CML monitoring results ensure that milestone “warning” responses are rapidly identified and acted upon, and may lower patient care costs.7Laboratory: CE-IVD and FDA cleared test with flexibility and simplicity for an easy, more optimized testing workflow.
- Flexible: Any number of samples, any day of the week with a fixed cost per reportable result, no wasted time or reagents from batching requirements.
- Simple Reporting: Results align to the IS automatically and are also shown in Molecular Response (MR) format. No additional work is required to align to the International Scale via Conversion Factors.t
- Easy: Automated processing provides consistent data, eliminates standard curve and replicate testing requirements, enables optimized lab organization
7 Goldberg S et al. First-line treatment selection and early monitoring patterns in chronic phase-chronic myeloid leukemia in routine clinical practice: SIMPLICITY. Am J Hematol. 2017 Nov 28;92:1214–1223. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5659133/